Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data.

Area of Science:

• Psychiatry and Pharmacology
• Neuroscience and Mental Health

Background:

• Agomelatine is an established treatment for major depressive disorder.
• Efficacy and safety data for agomelatine in bipolar depression are limited.

Purpose of the Study:

• To evaluate the preliminary antidepressant efficacy of agomelatine in bipolar I patients with a major depressive episode.
• To assess agomelatine's effectiveness as an adjunctive treatment with lithium or valpromide.

Main Methods:

• Open-label study involving 21 bipolar I patients (14 on lithium, 7 on valpromide) with severe depression (HAM-D-17 score ≥ 18).
• Patients received adjunctive agomelatine (25 mg/day) for at least 6 weeks, with an optional extension up to 46 weeks.
• Hamilton Rating Scale for Depression (HAM-D-17) was used for efficacy assessment.

Main Results:

• 81% of patients achieved marked improvement (≥50% reduction in HAM-D score) at study endpoint.
• Significant early response observed, with 47.6% responding within one week (baseline HAM-D: 25.2).
• No adverse event-related dropouts during the acute phase; some serious adverse events and manic switch episodes occurred during the extension period.

Conclusions:

• Agomelatine (25 mg) appears effective for treating depression in bipolar I patients co-medicated with lithium or valpromide.
• Further confirmation through a randomized controlled trial is warranted.
• The study provides preliminary evidence supporting agomelatine's role in managing bipolar depression.